Thursday, October 18, 2007 , Updated
Irving-based Reata Pharmaceuticals’ RTA 402 selected as one of the most promising new cancer drugs
IRVING — Reata Pharmaceuticals, Inc. today announced that its lead development candidate, RTA 402, has been selected as one of the top 10 most promising cancer drugs in development and available for strategic partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to executives in the biopharmaceutical industry.
Photo not provided by Reata Pharmaceuticals
Cancer, prepare to meet your maker
RTA 402 was selected from among hundreds of candidates through a rigorous screening process that assessed the strength of the agent’s scientific and clinical data along with its ultimate market potential. To be selected among the Top 10, products must distinguish themselves in each of these areas and represent a true breakthrough opportunity.
“Reata is very pleased that RTA 402 has been selected by Windhover as a Top 10 product,” commented Warren Huff, Reata’s CEO. “We believe this first-in-class drug has unique potential to become a major new cancer drug and are pleased that industry experts also see the significant opportunity RTA 402 represents.”
Source: Reata Pharmaceuticals
|
Email
|
Print
|
Comment
|
Tell us your story
|
-
»Dallas County to launch new prescription drug savings program
-
»Dallas jury returns $1.9 million verdict against Carrollton-based nutritional supplement provider AdvoCare
-
»Coppell-based Mannatech expanding to four additional European countries
-
»Dallas-based ACS acquires Pharm/DUR
-
»Coppell-based Mannatech reaches settlement with Texas Attorney General over deceptive trade practices
|
an event
|
a restaurant
|
|
a garage sale
|
a drink special
|
|
a movie showtime
|
local music
|
a job
|
a house
|
|
a deal
|
a pet
|
